Your browser is no longer supported. Please, upgrade your browser.
Settings
MDVN Medivation, Inc. daily Stock Chart
MDVN [NASD]
Medivation, Inc.
Index- P/E44.75 EPS (ttm)1.43 Insider Own1.20% Shs Outstand164.39M Perf Week2.17%
Market Cap10.52B Forward P/E29.14 EPS next Y2.20 Insider Trans-1.49% Shs Float162.47M Perf Month4.99%
Income252.70M PEG1.27 EPS next Q0.27 Inst Own93.00% Short Float1.97% Perf Quarter10.71%
Sales996.60M P/S10.56 EPS this Y-11.10% Inst Trans0.64% Short Ratio1.26 Perf Half Y95.69%
Book/sh5.48 P/B11.68 EPS next Y70.50% ROA21.50% Target Price64.82 Perf Year31.98%
Cash/sh- P/C- EPS next 5Y35.15% ROE34.00% 52W Range26.41 - 63.35 Perf YTD32.37%
Dividend- P/FCF34.99 EPS past 5Y50.90% ROI27.10% 52W High1.01% Beta0.85
Dividend %- Quick Ratio4.20 Sales past 5Y72.10% Gross Margin- 52W Low142.29% ATR1.21
Employees628 Current Ratio4.20 Sales Q/Q41.30% Oper. Margin40.20% RSI (14)67.61 Volatility1.99% 1.82%
OptionableYes Debt/Eq0.00 EPS Q/Q243.60% Profit Margin25.40% Rel Volume1.13 Prev Close62.49
ShortableYes LT Debt/Eq0.00 EarningsJul 26 AMC Payout0.00% Avg Volume2.53M Price63.99
Recom2.00 SMA203.18% SMA505.32% SMA20035.47% Volume2,859,168 Change2.40%
Jul-12-16Reiterated Wedbush Outperform $63 → $66
May-06-16Upgrade Citigroup Neutral → Buy
May-06-16Reiterated Barclays Overweight $48 → $70
May-05-16Reiterated Maxim Group Buy $47 → $76
May-02-16Reiterated Stifel Buy $52 → $66
May-02-16Reiterated Jefferies Hold $39 → $52
Apr-29-16Reiterated Wedbush Outperform $47 → $59
Apr-06-16Initiated Sun Trust Rbsn Humphrey Buy $56
Mar-31-16Reiterated Credit Suisse Outperform $48 → $49
Mar-30-16Initiated Goldman Neutral
Feb-19-16Initiated BofA/Merrill Buy
Feb-01-16Reiterated Wedbush Outperform $59 → $47
Jan-27-16Downgrade Canaccord Genuity Buy → Hold $90 → $45
Jan-21-16Initiated Credit Suisse Outperform
Nov-10-15Reiterated Maxim Group Buy $74 → $54
Nov-09-15Reiterated RBC Capital Mkts Sector Perform $50 → $40
Nov-06-15Reiterated UBS Buy $74 → $68
Nov-06-15Reiterated RBC Capital Mkts Sector Perform $50 → $40
Sep-28-15Reiterated Maxim Group Buy $171 → $74
Sep-16-15Initiated Nomura Buy
Jul-29-16 04:38PM  AbbVie, Merck Beat Earnings Estimates, But Sanofi Lags
06:14AM  MEDIVATION, INC. Files SEC form 8-K, Regulation FD Disclosure
03:59AM  Sanofi Quarterly Earnings, Sales Slide, but It Reiterates Discipline on Medivation
01:30AM  Sanofi Poised for Swift Medivation Move as Earnings Drop at Bloomberg
Jul-28-16 10:03AM  Short-Sellers Shy Away From These 2 Biotechs This Settlement Period
Jul-27-16 11:51AM  Medivation: When Earnings are an Afterthought at Barrons.com
Jul-26-16 09:39AM  Gilead Sciences: M&A Now? Please? at Barrons.com
07:00AM  Medivation Announces Second Quarter 2016 Financial Results Conference Call and Webcast on August 9, 2016 Marketwired
Jul-25-16 08:24AM  What's in Store for these 5 Drug Stocks in Q2 Earnings?
Jul-22-16 08:55AM  The Market In 5 Minutes: The Dow's Win Streak Comes To An End
Jul-20-16 03:00PM  Six Major Biotech Acquisitions You Could See In 2016 (Part 1) at Forbes
08:22AM  5 Merger Arb Plays Added to Havens Advisors Portfolio in Q2 at Insider Monkey
Jul-17-16 07:09PM  3 Stocks That Turned $5,000 into $100,000 or More at Motley Fool
Jul-15-16 09:06AM  Jazz Pharmaceuticals: How Much Return Potential Does It Have?
Jul-14-16 01:11PM  Ligand Pharmaceuticalss Performance Based on EV-to-EBITDA
01:11PM  Understanding Ligand Pharmaceuticalss PE Multiple
10:06AM  How Can Celators Portfolio Complement Jazz Pharmaceuticals?
Jul-13-16 03:51PM  Why Did Jazz Fall after Celator Acquisition Announcement?
11:46AM  10 Stocks That Had Their Price Targets Raised Tuesday at Insider Monkey
11:27AM  AstraZeneca Plans to Step into the Medivation Battle: a Threat for Sanofi?
09:05AM  Regenerons Dupilumab: How Much Potential Does It Hold?
Jul-12-16 03:59PM  Better Buy: Medivation, Inc. vs. Inovio Pharmaceuticals, Inc. at Motley Fool
03:27PM  AstraZeneca (AZN) Stock Up, Argus Research Initiates Coverage
Jul-11-16 10:56AM  Mondays Trending Stocks: CBS, Medivation, HPE, Boeing, Sagent Pharmaceuticals at Insider Monkey
09:40AM  Stocks Open Higher; Sony Trims Early Advance
Jul-08-16 05:57PM  [$$] Test Aids Prostate Cancer Treatment at The Wall Street Journal
Jul-07-16 04:06PM  Roche Said To Mull BioMarin Buyout, Driving Up Stock
02:36PM  Medivation Overplays a Risky Hand at Bloomberg
11:21AM  Medivation: Why Would They Even Consider Selling? at Barrons.com
10:48AM  This $10 billion drugmaker is the hottest thing in the industry and it knows it
08:23AM  Medivation Tries to Prove Its Worth
12:11AM  [$$] Test Aids Prostate Cancer Treatment at The Wall Street Journal
Jul-06-16 07:50PM  Buyout target Medivation says cancer drug could be "best in class"
05:33PM  Cancer drug discovered by UCLA sets off takeover fight among biotech companies at Los Angeles Times
04:12PM  MEDIVATION, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
02:40PM  Medivation Tells Big Pharma to Begin Bidding War at Motley Fool
02:37PM  Sanofi Plays HardballAnd Loses at Bloomberg
02:17PM  Pfizer, Celgene Pursue Medivation (PFE, CELG) at Investopedia
01:57PM  [$$] Medivation: scarcity value at Financial Times
01:51PM  [$$] Medivation confident drugs pipeline will win over suitors at Financial Times
09:45AM  Do Confidentiality Agreements Signal an Impending Medivation Acquisition? at 24/7 Wall St.
09:36AM  Medivation (MDVN) Stock Up on Potential Sanofi Deal
09:11AM  Blog Coverage Biotech Major Medivation Open to Takeover Talks
08:56AM  The Market In 5 Minutes: Gold Hits Highest Level Since 2014
08:44AM  Medivation Shares Spike as Company Opens Door to Full-Fledged Auction
08:40AM  Morning Movers: American Airlines Tumbles on Downgrade; Tesla Drops at Barrons.com
07:12AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Medivation, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
07:00AM  REMINDER: Medivation to Host Conference Call and Webcast Providing Detailed Review of Talazoparib on July 6, 2016 Business Wire
01:05AM  [$$] Medivation Opens Door to Takeover Talks With Sanofi at The Wall Street Journal
Jul-05-16 08:04PM  PRESS DIGEST- Financial Times - July 6 Reuters
06:54PM  Sanofi, Pfizer, Celgene may each pursue Medivation takeover at MarketWatch
06:21PM  [$$] Medivation Opens Door to Takeover Talks With Sanofi at The Wall Street Journal
05:59PM  An Auction Process Could Be on Medivation's Horizon
05:52PM  Medivation officially rejects latest Sanofi offer, may field more bids at MarketWatch
05:51PM  [$$] Medivation agrees to $10bn takeover talks at Financial Times
05:30PM  Medivation Agrees To Work With Sanofi After Nixing Higher Bid
05:20PM  Medivation agrees to open its books to Sanofi Reuters
04:54PM  Theres a bidding war brewing for a $10 billion drugmaker
04:48PM  MEDIVATION, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:29PM  Medivation enters several confidentiality agreements
04:25PM  Medivation Enters Talks With Sanofi, Others After Raised Bid at Bloomberg
04:15PM  Medivation Enters into Confidentiality Agreements, Including with Sanofi Business Wire
03:29PM  Exclusive: Medivation discusses potential sale to Sanofi - sources
Jul-01-16 04:00PM  Medivation Announces Conference Call and Webcast Providing Detailed Review of Talazoparib Marketwired
08:23AM  Merger and Acquisition Activity in the Biotech Sector Potentially on the Rise after Pfizers $5.2 Billion Purchase
Jun-30-16 12:36PM  5 Hot Stocks to Watch Right Now
11:01AM  [$$] Who Will Acquire Medivation? at Barrons.com
09:09AM  Merger and Acquisition Activity in the Biotech Sector Potentially on the Rise after Pfizers $5.2 Billion Purchase
Jun-29-16 06:40PM  This Biotechs Stock Just Doubled and Its Bad News for Sanofi at Fortune +5.47%
05:06PM  What Tesaro's Cancer Drug Success Means for Medivation
04:53PM  NetEase, Reynolds American Break Out, Other Top Stocks Retake Support
03:04PM  Stocks Higher As Banks, Oil Stocks Keep Bouncing
11:09AM  Biotech Gets Some Much-Needed Good News, From A Popular Target at Forbes
11:06AM  These 15 Biotech Companies Could Be Takeover Targets at Barrons.com
09:56AM  Tesaro Stock Bolts On Surprise Win For Ovarian Cancer Drug
09:40AM  Stocks Open Higher; Nike Reverses, Climbs
Jun-28-16 09:46AM  Faber Report: M&A updates
Jun-27-16 04:32PM  MEDIVATION, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Se
11:03AM  Medivation, Inc. breached its 50 day moving average in a Bearish Manner : MDVN-US : June 27, 2016
07:00AM  Medivation Voted Top Workplace in San Francisco Bay Area for Fourth Year in a Row Marketwired
04:51AM  Sanofi to Exit Animal Care in $25 Billion Asset Swap With Boehringer
Jun-24-16 04:18PM  MEDIVATION, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
02:19PM  Glass Lewis urges Medivation shareholders to support current board
08:30AM  Glass Lewis Recommends Medivations Stockholders Support the Companys Current Board Business Wire
Jun-23-16 05:50PM  Medivation Sends Letter to Stockholders to Set the Record Straight on Sanofis Misleading Claims Business Wire
05:01PM  Sanofi's Likely Sweetener for Medivation Panned
04:00PM  2 Words That Could Bring Down the Entire Prescription Drug Industry at Motley Fool
09:24AM  $18,543 Invested in This Biotech a Decade Ago Is Now Worth $1 Million at Motley Fool
08:56AM  The Market In 5 Minutes: It's Brexit Time
Jun-22-16 01:46PM  Sanofi Said to Consider Adding Future Payments to Medivation Bid at Bloomberg
Jun-20-16 06:25PM  NIH won't cut price of taxpayer-funded prostate cancer drug
Jun-17-16 12:25PM  BioMarin Takeout Rumors Swirl, Industry Insiders Aren't Convinced
09:56AM  Medivation's (MDVN) Pidilizumab Positive in Phase I/II Study
Jun-16-16 07:00AM  Medivation's Pidilizumab Shows Potential Clinical Benefit and Safety in Children With Diffuse Intrinsic Pontine Glioma (DIPG) Marketwired
Jun-14-16 08:30PM  MEDIVATION INVESTIGATION ALERT Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breaches of Fiduciary Duty - MDVN Business Wire
09:00AM  Medivation Has a Good Case for Patience at Bloomberg
Jun-13-16 05:32PM  MEDIVATION, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
05:01PM  Medivation Urges Shareholders to Reject Sanofi Proposal
12:50PM  UPDATE 1-Sanofi, Medivation advance to next phase of takeover fight Reuters
09:33AM  Sanofi files request to replace Medivation board Reuters
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of medical therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (CRPC) patients. The company also develops Enzalutamide, which is in phase III clinical trials for the treatment of non-metastatic CRPC, and metastatic and non-metastatic hormone sensitive prostate cancer; and phase II clinical trials for the treatment of hepatocellular carcinoma, androgen receptor positive (AR+) triple negative breast cancer, estrogen receptor positive or progesterone receptor positive and human epidermal growth factor receptor 2 (HER2) normal breast cancer, and AR+ HER2 amplified breast cancer. In addition, it develops Talazoparib, which is in phase II clinical trials for treatment of germline mutated HER2 normal breast cancer; Pidilizumab that is in phase II clinical trials for the treatment of relapsed or refractory diffuse large B-cell lymphoma; and MDV4463, which is in phase I clinical trials for the treatment of nonalcoholic steatohepatitis. The company has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI; and License and Manufacturing and supply agreement with CureTech, Ltd. for the development, manufacture, and commercialization of biologic molecules. Medivation, Inc. is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Powell Andrew Kenneth WilliamSVP, General Counsel & Crp SecJun 06Sale60.422,578155,76328,517Jun 06 08:10 PM
Bierly RickCFO (former)May 06Sale60.126,315379,63728,744May 09 05:35 PM
Bierly RickCFO (former)May 05Sale59.204,025238,28035,059May 09 05:35 PM
Svoronos DawnDirectorMar 14Sale38.906,000233,40018,234Mar 16 05:06 PM
Hirmand MohammadInterim Chief Medical OfficerMar 04Sale41.101,52562,68539,342Mar 07 08:44 PM
Bierly RickChief Financial OfficerMar 04Sale40.002,998119,92039,084Mar 07 08:43 PM
Hung DavidPresident and CEOFeb 04Sale31.186,350197,9931,504,654Feb 05 07:05 PM
Machado Clarence PatrickDirectorJan 19Option Exercise3.3775,000252,525141,156Jan 21 05:45 PM
Machado Clarence PatrickDirectorJan 19Sale37.3475,0002,800,56266,156Jan 21 05:45 PM
Lobacki Joseph MChief Commercial OfficerJan 04Sale46.503,065142,52319,365Jan 05 06:14 PM
VERNON W ANTHONYDirectorDec 14Buy40.6915,000610,35028,704Dec 16 05:40 PM
Hung DavidPresident and CEODec 03Sale43.1010,950471,9661,511,004Dec 04 04:36 PM
Hirmand MohammadInterim Chief Medical OfficerDec 03Sale43.401,07546,65531,113Dec 04 04:35 PM
Hirmand MohammadInterim Chief Medical OfficerNov 09Sale41.912329,72232,188Nov 12 06:46 PM
Svoronos DawnDirectorSep 08Sale89.153,100276,36512,117Sep 08 07:39 PM